Nabil Izzaatie Mohamad Safiai

Nabil Izzaatie Mohamad Safiai

Auto-generated profile, based on publicly available information

Nabil Izzaatie Mohamad Safiai

Universiti Putra Malaysia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2022 in Cephalalgia
Verified
Journal Article
Closed access
NSNabil Izzaatie Mohamad Safiai
Nabil Izzaatie Mohamad Safiai
NMNur Afiqah Mohamad
Nur Afiqah Mohamad
HBHamidon Basri
Hamidon Basri
LMLiyana Najwa Inche Mat
Liyana Najwa Inche Mat
FHFan Kee Hoo
Fan Kee Hoo
WSWan Aliaa Wan Sulaiman
Wan Aliaa Wan Sulaiman
Objective: To evaluate the efficacy of high-frequency repetitive transcranial magnetic stimulation over dorsolateral prefrontal cortex as a migraine prevention by conducting a systematic review and meta-analysis. Background: The efficacy of high-frequency repetitive transcranial magnetic stimulation over dorsolateral prefrontal cortex as preventive migraine treatment remains debatable. Methods: PubMed, Scopus, CINAHL, CENTRAL, and BioMed Central databases were searched from their inception until December 2020. Randomised trials comparing high-frequency repetitive transcranial magnetic stimulation over dorsolateral prefrontal cortex with sham for migraine prevention were included. The risk of bias was assessed using the Cochrane guidelines. Headache days, pain intensity, acute medication intake, and disability were extracted as study outcomes and the mean difference with a random-effects model was used to determine the effect size. Results: Meta-analysis revealed that high-frequency repetitive transcranial magnetic stimulation over dorsolateral prefrontal cortex significantly reduced acute medication intake (Mean Difference = 9.78, p = 0.02, 95%CI: 1.60, 17.96, p = 0.02) and functional disability (Mean Difference = 8.00, p < 0.05, 95%CI: 4.21, 11.79). However, no differences were found in headache days and pain intensity reduction, although there was a slight trend favouring high-frequency repetitive transcranial magnetic stimulation. Conclusion: High-frequency repetitive transcranial magnetic stimulation over dorsolateral prefrontal cortex may be effective in reducing acute medication intake and disability. However, more studies are needed to strengthen this preliminary evidence.

17 June 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NSNabil Izzaatie Mohamad Safiai
Nabil Izzaatie Mohamad Safiai
NMNur Afiqah Mohamad
Nur Afiqah Mohamad
HBHamidon Basri
Hamidon Basri
LMLiyana Najwa Inche Mat
Liyana Najwa Inche Mat
FHFan Kee Hoo
Fan Kee Hoo
WSWan Aliaa Binti Wan Sulaiman
Wan Aliaa Binti Wan Sulaiman
Background: Migraine may lead to a negative impact on the patients’ quality of life with a subsequent substantial burden to society. Therapy options for treatment and prevention of migraine have progressed over the years and repetitive transcranial magnetic stimulation (rTMS) is one of the promising non-pharmacological options. It induces and alters electric current in the brain via repetitive non-invasive brain stimulation in high frequency. In migraine patients, two common stimulation sites are the M1 cortex and dorsolateral prefrontal cortex (DLPFC). The mechanism on how rTMS exerts therapeutic effects on migraine is not fully established, but the main postulation is that the neuromodulation via high-frequency rTMS (hf-rTMS) might inhibit pain perception. However, evidence from studies has been conflicting, thus the usefulness of hf-rTMS as migraine preventive treatment is still uncertain at this moment. Methods: This is a systematic review protocol describing essential reporting items based on the PRISMA for systematic review protocols (PRISMA-P) (Registration number: CRD42020220636). We aim to review the effectiveness, tolerability, and safety of hf-rTMS at DLPFC in randomised controlled trials (RCTs) as migraine prophylactic treatment. We will search Scopus, Cumulative Index to Nursing and Allied Health Literature Plus, PubMed, Cochrane Central Register of Controlled Trials and Biomed Central for relevant articles from randomised controlled clinical trials that used hf-rTMS applied at DLPFC for the treatment of migraine. The risk of bias will be assessed using the version 2 “Risk of bias” tool from Cochrane Handbook for Systematic Reviews of Interventions Version 6.1. We will investigate the evidence on efficacy, tolerability and safety and we will compare the outcomes between the hf-rTMS intervention and sham groups. Discussion: This systematic review will further determine the efficacy, safety, and tolerability of hf-rTMS applied at DLPFC for migraine prophylaxis. It will provide additional data for health practitioners and policymakers about the usefulness of hf-rTMS for migraine preventive treatment.

11 November 2020 in Trials
Verified
Journal Article
Open access
PDF file
NSNabil Izzaatie Mohamad Safiai
Nabil Izzaatie Mohamad Safiai
NANur Ain Amir
Nur Ain Amir
HBHamidon Basri
Hamidon Basri
LMLiyana Najwa Inche Mat
Liyana Najwa Inche Mat
FHFan Kee Hoo
Fan Kee Hoo
WSWan Aliaa Binti Wan Sulaiman
Wan Aliaa Binti Wan Sulaiman
Background: This is a phase II randomised, double-blind, sham-controlled trial to evaluate the effectiveness and tolerability of repetitive transcranial magnetic stimulation for preventive treatment of episodic migraine amongst migraine subjects.Methods: Subjects age 18 to 60 years will undergo a baseline evaluation to establish the diagnosis of migraine based on the International Classification of Headache Disorder 3rd Edition (ICHD-3). Those who fulfil the ICHD-3 criteria for episodic migraine and compliant to the headache diary during a month run-in period will be enrolled. A total of 76 subjects will be randomised to receive either transcranial magnetic stimulation or sham stimulation for 5 sessions within 2 weeks duration. Follow-up sessions will be conducted monthly for three consecutive months. Prior to treatment, subjects will be required to fill up questionnaires and undergo few procedures such as electroencephalography, transcranial Doppler ultrasound and biochemical analysis for serum serotonin, serum calcitonin gene-related peptide and serum beta-endorphin. These procedures will be repeated at month 3 after receiving the last treatment. The primary outcome measure of this study is the difference in mean monthly migraine days at baseline and at months 1, 2 and 3 after treatment sessions.Discussion: Following evidence from previous studies showing restoration of dorsolateral prefrontal cortex (DLPFC) activation to almost normal level, the rTMS intervention will target left DLPFC in this study. An intermediate duration of treatment sessions is selected for this study. It is set to five treatment sessions given within 2 weeks duration.Trial registration: ClinicalTrials.govNCT03556722. Registered on 14 June 2018

29 August 2020 in Research Square
Verified
Preprint
Open access
PDF file
NSNabil Izzaatie Mohamad Safiai
Nabil Izzaatie Mohamad Safiai
NANur Ain Amir
Nur Ain Amir
HBHamidon bin Basri
Hamidon bin Basri
LMLiyana Najwa Inche Mat
Liyana Najwa Inche Mat
FHFan Kee Hoo
Fan Kee Hoo
WSWan Aliaa Binti Wan Sulaiman
Wan Aliaa Binti Wan Sulaiman
Background: This is a phase II randomised, double-blind, sham-controlled trial to evaluate the effectiveness and tolerability of repetitive transcranial magnetic stimulation for preventive treatment of episodic migraine among migraine subjects. Methods: Subjects age 18 to 60 years will undergo a baseline evaluation to establish the diagnosis of migraine based on International Classification of Headache Disorder 3rd Edition (ICHD-3). Those who fulfil the ICHD-3 criteria for episodic migraine and compliant to the headache diary during a month run-in period will be enrolled. A total of 76 subjects will be randomised to receive either transcranial magnetic stimulation or sham stimulation for 5 sessions within 2 weeks duration. Follow-up sessions will be conducted monthly for three consecutive months. Prior to treatment, subjects will be required to fill up questionnaires and undergo few procedures such as electroencephalography, transcranial doppler ultrasound and biochemical analysis for serum serotonin, serum calcitonin-gene related peptide and serum beta-endorphin. These procedures will be repeated at month 3 after receiving last treatment. The primary outcome measure of this study is the difference in mean monthly migraine days at baseline and at month 1, 2 and 3 after treatment sessions. Discussion: Following evidence from previous studies showing restoration of dorsolateral prefrontal cortex (DLPFC) activation to almost normal level, the rTMS intervention will target left DLPFC in this study. Meanwhile, the least number of treatment sessions reported which proved to be effective in reducing migraine days was three session of rTMS given in alternate days. Hence, an intermediate duration of treatment sessions is selected for this study. It is set to five treatment sessions given within 2 weeks duration. Trial registration: NCT03556722. Transcranial Magnetic Stimulation in Episodic Migraine (Magnet-EM) was registered on 27th April 2018. https://clinicaltrials.gov/ct2/show/NCT03556722.

12 February 2020 in Research Square
Verified
Preprint
Open access
PDF file
NSNabil Izzaatie Mohamad Safiai
Nabil Izzaatie Mohamad Safiai
NANur Ain Amir
Nur Ain Amir
HBHamidon bin Basri
Hamidon bin Basri
LMLiyana Najwa Inche Mat
Liyana Najwa Inche Mat
FHFan Kee Hoo
Fan Kee Hoo
WSWan Aliaa Binti Wan Sulaiman
Wan Aliaa Binti Wan Sulaiman
Background This is a phase II randomised, double-blind, placebo-controlled trial to evaluate the effectiveness and tolerability of repetitive transcranial magnetic stimulation for preventive treatment of episodic migraine among migraine subjects. Methods Subjects age 18 to 60 years will undergo a baseline evaluation to ascertain the diagnosis of migraine based on International Classification of Headache Disorder 3 rd Edition (ICHD-3). Only those who fulfil the ICHD-3 criteria for episodic migraine and compliant to the headache diary during a month run-in period will be enrolled. A total of 76 subjects will be randomised to receive either transcranial magnetic stimulation or placebo for 5 sessions within 2 weeks duration. Follow up sessions will be conducted monthly for three consecutive months. Prior to treatment, subjects will be required to fill up questionnaires and undergo few procedures such as electroencephalography, transcranial doppler ultrasound and biochemical analysis for serum serotonin, serum calcitonin-gene related peptide and serum beta-endorphin. These procedures will be repeated post-treatment during their last visit. The primary outcome measure of this study is the difference in mean monthly migraine days at baseline and at month 1, 2 and 3 after treatment sessions. Discussion Following evidence from previous studies showing restoration of dorsolateral prefrontal cortex (DLPFC) activation to near normal level, the rTMS intervention will target left DLPFC in this study. Meanwhile, in terms of treatment frequency, the least number of sessions reported which proved to be effective in treating migraine was three session of rTMS given in alternate days. Hence, for this study, an intermediate duration of treatment sessions is selected. It is set to five treatment sessions given within 2 weeks duration.

20 October 2020 in Research Square
Verified
Preprint
Open access
PDF file
NSNabil Izzaatie Mohamad Safiai
Nabil Izzaatie Mohamad Safiai
NANur Ain Amir
Nur Ain Amir
HBHamidon bin Basri
Hamidon bin Basri
LMLiyana Najwa Inche Mat
Liyana Najwa Inche Mat
FHFan Kee Hoo
Fan Kee Hoo
WSWan Aliaa Binti Wan Sulaiman
Wan Aliaa Binti Wan Sulaiman
Background: This is a phase II randomised, double-blind, sham-controlled trial to evaluate the effectiveness and tolerability of repetitive transcranial magnetic stimulation for preventive treatment of episodic migraine among migraine subjects. Methods: Subjects age 18 to 60 years will undergo a baseline evaluation to establish the diagnosis of migraine based on International Classification of Headache Disorder 3rd Edition (ICHD-3). Those who fulfil the ICHD-3 criteria for episodic migraine and compliant to the headache diary during a month run-in period will be enrolled. A total of 76 subjects will be randomised to receive either transcranial magnetic stimulation or sham stimulation for 5 sessions within 2 weeks duration. Follow-up sessions will be conducted monthly for three consecutive months. Prior to treatment, subjects will be required to fill up questionnaires and undergo few procedures such as electroencephalography, transcranial doppler ultrasound and biochemical analysis for serum serotonin, serum calcitonin-gene related peptide and serum beta-endorphin. These procedures will be repeated at month 3 after receiving last treatment. The primary outcome measure of this study is the difference in mean monthly migraine days at baseline and at month 1, 2 and 3 after treatment sessions. Discussion: Following evidence from previous studies showing restoration of dorsolateral prefrontal cortex (DLPFC) activation to almost normal level, the rTMS intervention will target left DLPFC in this study. An intermediate duration of treatment sessions is selected for this study. It is set to five treatment sessions given within 2 weeks duration. Trial registration: NCT03556722. Transcranial Magnetic Stimulation in Episodic Migraine (Magnet-EM) was registered on 27th April 2018. https://clinicaltrials.gov/ct2/show/NCT03556722.